Showing Results for
- Academic Journals (18)
Search Results
- 18
Academic Journals
- 18
-
From:Future Oncology (Vol. 11, Issue 3) Peer-ReviewedAuthor(s): Filippo de Marinis [*] aff1 aff2 , Alain Vergnenegre aff3 , Antonio Passaro aff1 aff2 , Catherine Dubos-Arvis aff4 , Enric Carcereny aff5 , Ana Drozdowskyj aff6 , Ali Zeaiter aff7 , Pablo Perez-Moreno aff7 ,...
-
From:Future Oncology (Vol. 11, Issue 3) Peer-ReviewedAuthor(s): Brian Seal aff1 , Sean D Sullivan aff2 , Scott Ramsey aff3 , Carl V Asche aff4 , Kenneth M Shermock aff5 , Syam Sarma aff6 , Erin Zagadailov aff7 , Eileen Farrelly aff7 , Michael Eaddy [*] aff7 KEYWORDS...
-
From:Future Oncology (Vol. 11, Issue 3) Peer-ReviewedAuthor(s): Athina Markou aff1 , Evi Lianidou aff1 , Vassilis Georgoulias [*] aff2 KEYWORDS circulating miRNAs; liquid biopsy; metastasis; miRNAs; tumor biomarkers Metastasis refers to the spread of cancer cells...
-
From:Future Oncology (Vol. 11, Issue 3) Peer-ReviewedAuthor(s): Lindsay C Stansfield aff1 , Wilson I Gonsalves [*] aff2 , Francis K Buadi aff2 KEYWORDS hepatic impairment; myeloma; novel agents Multiple myeloma (MM) is a clonal plasma cell disorder, which...
-
From:Future Oncology (Vol. 11, Issue 3) Peer-ReviewedAuthor(s): Peter Gorayski aff1 , Bryan Burmeister aff1 aff2 , Matthew Foote [*] aff1 aff2 KEYWORDS cutaneous; melanoma; radiation therapy; radiotherapy; targeted therapies In 2014, melanoma accounted for 76,100...
-
From:Future Oncology (Vol. 11, Issue 3) Peer-ReviewedAuthor(s): Luigi Bolondi [*] aff1 , Antonio Craxi aff2 , Franco Trevisani aff3 , Bruno Daniele aff4 , Giovan Giuseppe Di Costanzo aff5 , Stefano Fagiuoli aff6 , Calogero Cammà aff7 , Paolo Bruzzi aff8 , Romano Danesi...
-
From:Future Oncology (Vol. 11, Issue 3) Peer-ReviewedAuthor(s): Fenlai Tan aff1 , Yuankai Shi aff2 , Yinxiang Wang aff1 , Lieming Ding aff1 , Xiaobin Yuan aff1 , Yan Sun [*] aff2 KEYWORDS EGF receptor tyrosine kinase inhibitors; icotinib; molecular targeted therapy;...
-
From:Future Oncology (Vol. 11, Issue 3) Peer-ReviewedABSTRACT Satisfactory treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) is not currently available and novel therapies are needed. mTOR is an intracellular kinase that is part of an aberrantly...
-
From:Future Oncology (Vol. 11, Issue 3) Peer-ReviewedAuthor(s): Cristiana Tanase [*] aff1 , Radu Albulescu aff1 aff2 , Elena Codrici aff1 , Ionela Daniela Popescu aff1 , Simona Mihai aff1 , Ana Maria Enciu aff1 aff3 , Maria Linda Cruceru aff3 , Adrian Claudiu Popa aff3 ,...
-
From:Future Oncology (Vol. 11, Issue 3) Peer-ReviewedAuthor(s): Stefano Rausei [*] aff1 , Laura Ruspi aff1 , Alberto Mangano aff1 , Georgios D Lianos aff2 , Federica Galli aff1 , Luigi Boni aff1 , Dimitrios H Roukos aff2 , Gianlorenzo Dionigi aff1 KEYWORDS gastric...
-
From:Future Oncology (Vol. 11, Issue 3) Peer-ReviewedAuthor(s): Kashyap Shatagopam aff1 , Hristos Z Kaimakliotis [*] aff1 , Liang Cheng aff2 , Michael O Koch aff1 KEYWORDS bladder cancer; chemotherapy; prostate cancer; radiotherapy; small cell carcinoma; surgery...
-
From:Future Oncology (Vol. 11, Issue 3) Peer-ReviewedAuthor(s): Sanjay Popat [*] aff1 , Anders Mellemgaard aff2 , Kyle Fahrbach aff3 , Alison Martin aff4 , Maria Rizzo aff4 , Rolf Kaiser aff5 , Ingolf Griebsch aff5 , Martin Reck aff6 KEYWORDS adenocarcinoma;...
-
From:Future Oncology (Vol. 11, Issue 3) Peer-ReviewedAuthor(s): Alessandra Fabi [*] aff1 , Luca Moscetti aff2 , Mariangela Ciccarese aff3 , Miriam Caramanti aff4 , Nello Salesi aff5 , Nicla La Verde aff6 , Michelangelo Russillo aff7 , Daniele Generali aff8 , Giuseppina...
-
From:Future Oncology (Vol. 11, Issue 3) Peer-ReviewedAuthor(s): Ravi Salgia [*] KEYWORDS ALK inhibitor; EGFR inhibitor; integrated medicine; molecular diagnostics; molecular profile; multidisciplinary forum; non-small-cell lung cancer; personalized medicine Lung...
-
From:Future Oncology (Vol. 11, Issue 3) Peer-ReviewedFollowing publication of the Review by Christine M Bestvina, Leah L Zullig & S Yousuf Zafar, titled 'The implications of out-of-pocket cost of cancer treatment in the USA: a critical appraisal of the literature', which...
-
From:Future Oncology (Vol. 11, Issue 3) Peer-ReviewedAuthor(s): Chunhuan Lao [*] aff1 , Charis Brown aff1 , Paul Rouse aff2 , Richard Edlin aff3 , Ross Lawrenson aff1 KEYWORDS cost; cost-effectiveness threshold; economic evaluation; prostate cancer; quality of life;...
-
From:Future Oncology (Vol. 11, Issue 3) Peer-ReviewedAuthor(s): Jose A Pedrosa aff1 , Michael O Koch aff1 , Hristos Z Kaimakliotis aff1 , M Francesca Monn aff1 , Timothy A Masterson aff1 , Kevin R Rice aff1 , K Clint Cary aff1 , Richard S Foster aff1 , Richard Bihrle aff1...
-
From:Future Oncology (Vol. 11, Issue 3) Peer-ReviewedAuthor(s): Romain Guiho aff1 aff2 aff3 , Kevin Biteau aff1 aff2 aff3 , Dominique Heymann aff1 aff2 aff3 , Françoise Redini [*] aff1 aff2 aff3 KEYWORDS Ewing's sarcoma; microenvironment; osteosarcoma; resistance;...